KT&G Corp. to expand HNB product line in Korea

Nov.10.2022
KT&G Corp. to expand HNB product line in Korea
South Korea's major tobacco company, KT&G Corp., is adding new HNB products to its product line.

Seoul, Nov. 9 (Yonhap) -- South Korean major tobacco company, KT&G Corp., announced on Wednesday that they will introduce a new HNB (Heat-Not-Burn) product to the domestic market to diversify their product lineup, which currently focuses on cigarettes.


The company stated in a press release that on November 16, KT&G will launch a promotional campaign for their heat-not-burn (HNB) tobacco product named lil ABLE and its premium version, lil ABLE PREMIUM, for local consumers.


HNB products are electronic devices that contain tobacco, which distinguishes them from e-cigarettes. The tobacco is heated to high temperatures instead of being ignited, producing smoke that the user inhales.


During the July-September quarter, KT&G's net profit surged 29% to 463 billion Korean won (approximately 2.4 billion Chinese yuan) from 359 billion Korean won a year earlier, thanks to increased exports and a weakening Korean won.


Currently, 90% of KT&G's total sales come from the cigarette business sector, with the remaining 10% coming from their HNB (Heat-Not-Burn) department. The company has been actively working to increase sales in their non-cigarette business sectors.


From January to September, net income increased by 21% from the same period last year, rising from 878.58 billion Korean won to 1.06 trillion Korean won (approximately 5.6 billion yuan).


New product line "Lil Able Series." Image source: Hankyoreh.


Statement:


This article is compiled from third-party information and is intended solely for industry exchange and learning purposes.


This article does not represent the views of 2FIRSTS and 2FIRSTS is not able to confirm the authenticity or accuracy of the article's content. The translation of this article is intended solely for industry exchange and research.


Due to limitations in translation ability, the compiled article may not fully reflect the original text. Please refer to the original text for accurate representation.


2FIRSTS asserts complete alignment with the Chinese government on any domestic, Hong Kong, Macau, Taiwan, or international issues and positions.


The compilation of information is owned by the original media and author. If there is any infringement, please contact us for deletion.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Pakistan Senate health panel weighs possible vape ban
Pakistan Senate health panel weighs possible vape ban
Sources say Pakistan’s Senate Standing Committee on Health is deliberating whether to impose a ban on vaping products, after holding a meeting on the health implications of vaping and the rising use of e-cigarettes nationwide.
Mar.04 by 2FIRSTS.ai
Special Report | Tax Veteran Takes Helm at China’s Tobacco Regulator, Leadership Change Fuels Reform Watch
Special Report | Tax Veteran Takes Helm at China’s Tobacco Regulator, Leadership Change Fuels Reform Watch
China’s tobacco system has appointed a new top internal leader with a long background in public finance and taxation, drawing renewed attention to whether the country’s tobacco monopoly may enter a new phase of reform debate. The appointment itself does not signal a defined policy shift.But it places a veteran fiscal official at the center of a key state sector amid unresolved questions on tax reform, structure, and emerging tobacco products.
Mar.20
FDA nicotine pouch review delay report knocks tobacco shares lower
FDA nicotine pouch review delay report knocks tobacco shares lower
After Reuters reported before the market open that FDA reviews of nicotine pouch applications could face delays, shares of Philip Morris International, Turning Point Brands and British American Tobacco fell on April 1, underscoring the direct impact of U.S. regulatory signals on major tobacco companies and nicotine pouch expectations.
Apr.02
Special Report | China’s Two Sessions Revisit Consumption Tax Reform, Tobacco Tax Outlook Draws Attention
Special Report | China’s Two Sessions Revisit Consumption Tax Reform, Tobacco Tax Outlook Draws Attention
China’s 2026 “Two Sessions” again raised the issue of consumption tax reform. As the largest source of consumption tax revenue, the tobacco tax system—its collection stages, tax structure and regional revenue distribution—has re-entered the policy discussion. This article outlines the structure of China’s tobacco consumption tax, past adjustments and key areas of debate, providing international readers with background on one of the country’s most important tax categories.
Special Report
Mar.08
Malaysia joint operation seized $19,000 worth of vape liquid in Likas
Malaysia joint operation seized $19,000 worth of vape liquid in Likas
More than 2,300 units of vape liquid worth over RM75,000 were seized during an integrated operation at premises in Likas near Kota Kinabalu. During Ops Taring Landai E-Cigarette Mega on Feb 10 night, the Marine Police, Sabah Health Department officials and district police detected a shop displaying 92 types of vape pods and, after further searches, found 2,353 units of vape liquid stored on the premises.
Feb.11 by 2FIRSTS.ai
PMTA Roundtable Opens with Industry Questioning Product Characterization Standards, FDA Defends Regulatory Boundaries
PMTA Roundtable Opens with Industry Questioning Product Characterization Standards, FDA Defends Regulatory Boundaries
At the opening of FDA’s PMTA roundtable, small ENDS manufacturers warned that unclear product characterization standards are limiting their ability to invest and raise capital. FDA officials acknowledged industry concerns but said regulatory flexibility is constrained by statutory and procedural boundaries.
Feb.11